
Ulcerative Colitis - Pipeline Insight, 2025
Description
DelveInsight’s, “Ulcerative Colitis - Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ulcerative Colitis: Overview
Ulcerative colitis is an idiopathic inflammatory condition of the colon that results in diffuse friability and superficial erosions on the colonic wall associated with bleeding. It is the most common form of inflammatory bowel disease worldwide. It characteristically involves inflammation restricted to the mucosa and submucosa of the colon. Typically, the disease starts in the rectum and extends proximally in a continuous manner. In the United States, the disease accounts for a quarter-million provider visits annually, and medical costs directly related to the disease are estimated to exceed four billion dollars annually. The specific cause of inflammatory bowel disease is not known. There seems to be a primary genetic component since the most important independent risk factor is a family history of the disease (8% to 14% of patients). A first-degree relative of a patient with ulcerative colitis has a four times higher risk of developing the disease. Additionally, ulcerative colitis has a higher incidence in Jewish populations than other ethnicities. The pathophysiology of ulcerative colitis involves defects in the epithelial barrier, immune response, leukocyte recruitment, and microflora of the colon. The epithelial barrier has a defect in colonic mucin and possibly tight junctions, leading to increased uptake of luminal antigens. The lamina propria of the mucosa also has an increased number of activated and mature dendritic cells, which include a large number of toll-like receptors (TLR), specifically TLR2 and TLR4. There also seems to be an atypical T-helper (Th) cell response in patients with ulcerative colitis, specifically Th2, which exerts a cytotoxic response against epithelial cells. Leukocyte recruitment is affected on two fronts. There is an upregulated release of the chemoattractant CXCL8 in ulcerative colitis so that leukocytes are recruited to the mucosa from systemic circulation. Additionally, there is an upregulation of mucosal cellular adhesion molecule-1 (Mad-CAM1) on the endothelium of mucosal blood vessels, which promotes leukocyte adhesion and extravasation into mucosal tissue. Studies have shown that enteric microflora is important in the pathogenesis and severity of inflammation and disease phenotype. Ulcerative colitis seems also to result, in part, from a homeostatic imbalance between enteric microflora and the host's mucosal immunity. This results in an aberrant response to non-pathogenic bacteria.
Ulcerative colitis is diagnosed clinically with supportive findings on endoscopy, biopsy, and negative stool examination for infectious causes. Radiologic examinations are not critical for diagnosis but may be useful. Colonoscopy or proctosigmoidoscopy might reveal loss of typical vascular pattern, granularity, friability, and ulceration, which involve the distal rectum and proceed proximally in a symmetric, continuous, and circumferential pattern. Laboratory evaluation will usually reveal an increase in inflammatory factors, especially during an acute flare. An endoscopy (colonoscopy) must be done at some point which will reveal fragile mucosa, granular mucosa, loss of vascular pattern, presence of erosions and pseudopolyposis. Multiple biopsies should be obtained to confirm the diagnosis. The most common classification system used to determine the extent and severity of the disease is the Montreal classification system. Treatment choice for patients with ulcerative colitis is based on both the extent of the disease and the severity. The prognosis during the first decade after diagnosis is often generally good, and most patients go into remission. Rectal application of medical therapy, via suppository or enema, is usually appropriate for isolated distal disease (proctitis); however, a rectal application is usually used in combination with systemic therapy to help target the distal colon and, therefore, decrease tenesmus. Ulcerative colitis can be treated with medications such as aminosalicylates, glucocorticoids, thiopurines, and biological drugs. Probiotics and fecal microbiota transplantation may also be helpful. Colectomy is curative in patients with ulcerative colitis. Colonoscopy is recommended at regular intervals due to the risk of colon cancer. There is no specific diet for patients with ulcerative colitis, but lactose intolerance is common.
“Ulcerative Colitis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Ulcerative Colitis pipeline landscape is provided which includes the disease overview and Ulcerative Colitis treatment guidelines. The assessment part of the report embraces, in depth Ulcerative Colitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative Colitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Ulcerative Colitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ulcerative Colitis Emerging Drugs
Further product details are provided in the report……..
Ulcerative Colitis: Therapeutic Assessment
This segment of the report provides insights about the different Ulcerative Colitis drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 75+ products under different phases of clinical development like
Ulcerative Colitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ulcerative Colitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Colitis drugs.
Ulcerative Colitis Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 7-8 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Ulcerative Colitis: Overview
Ulcerative colitis is an idiopathic inflammatory condition of the colon that results in diffuse friability and superficial erosions on the colonic wall associated with bleeding. It is the most common form of inflammatory bowel disease worldwide. It characteristically involves inflammation restricted to the mucosa and submucosa of the colon. Typically, the disease starts in the rectum and extends proximally in a continuous manner. In the United States, the disease accounts for a quarter-million provider visits annually, and medical costs directly related to the disease are estimated to exceed four billion dollars annually. The specific cause of inflammatory bowel disease is not known. There seems to be a primary genetic component since the most important independent risk factor is a family history of the disease (8% to 14% of patients). A first-degree relative of a patient with ulcerative colitis has a four times higher risk of developing the disease. Additionally, ulcerative colitis has a higher incidence in Jewish populations than other ethnicities. The pathophysiology of ulcerative colitis involves defects in the epithelial barrier, immune response, leukocyte recruitment, and microflora of the colon. The epithelial barrier has a defect in colonic mucin and possibly tight junctions, leading to increased uptake of luminal antigens. The lamina propria of the mucosa also has an increased number of activated and mature dendritic cells, which include a large number of toll-like receptors (TLR), specifically TLR2 and TLR4. There also seems to be an atypical T-helper (Th) cell response in patients with ulcerative colitis, specifically Th2, which exerts a cytotoxic response against epithelial cells. Leukocyte recruitment is affected on two fronts. There is an upregulated release of the chemoattractant CXCL8 in ulcerative colitis so that leukocytes are recruited to the mucosa from systemic circulation. Additionally, there is an upregulation of mucosal cellular adhesion molecule-1 (Mad-CAM1) on the endothelium of mucosal blood vessels, which promotes leukocyte adhesion and extravasation into mucosal tissue. Studies have shown that enteric microflora is important in the pathogenesis and severity of inflammation and disease phenotype. Ulcerative colitis seems also to result, in part, from a homeostatic imbalance between enteric microflora and the host's mucosal immunity. This results in an aberrant response to non-pathogenic bacteria.
Ulcerative colitis is diagnosed clinically with supportive findings on endoscopy, biopsy, and negative stool examination for infectious causes. Radiologic examinations are not critical for diagnosis but may be useful. Colonoscopy or proctosigmoidoscopy might reveal loss of typical vascular pattern, granularity, friability, and ulceration, which involve the distal rectum and proceed proximally in a symmetric, continuous, and circumferential pattern. Laboratory evaluation will usually reveal an increase in inflammatory factors, especially during an acute flare. An endoscopy (colonoscopy) must be done at some point which will reveal fragile mucosa, granular mucosa, loss of vascular pattern, presence of erosions and pseudopolyposis. Multiple biopsies should be obtained to confirm the diagnosis. The most common classification system used to determine the extent and severity of the disease is the Montreal classification system. Treatment choice for patients with ulcerative colitis is based on both the extent of the disease and the severity. The prognosis during the first decade after diagnosis is often generally good, and most patients go into remission. Rectal application of medical therapy, via suppository or enema, is usually appropriate for isolated distal disease (proctitis); however, a rectal application is usually used in combination with systemic therapy to help target the distal colon and, therefore, decrease tenesmus. Ulcerative colitis can be treated with medications such as aminosalicylates, glucocorticoids, thiopurines, and biological drugs. Probiotics and fecal microbiota transplantation may also be helpful. Colectomy is curative in patients with ulcerative colitis. Colonoscopy is recommended at regular intervals due to the risk of colon cancer. There is no specific diet for patients with ulcerative colitis, but lactose intolerance is common.
“Ulcerative Colitis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Ulcerative Colitis pipeline landscape is provided which includes the disease overview and Ulcerative Colitis treatment guidelines. The assessment part of the report embraces, in depth Ulcerative Colitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative Colitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis R&D. The therapies under development are focused on novel approaches to treat/improve Ulcerative Colitis.
This segment of the Ulcerative Colitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ulcerative Colitis Emerging Drugs
- Obefazimod: Abivax
- ABBV-668: AbbVie
- TEV-48574: Teva Pharmaceutical
- SOR102: Sorriso Pharmaceuticals
Further product details are provided in the report……..
Ulcerative Colitis: Therapeutic Assessment
This segment of the report provides insights about the different Ulcerative Colitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ulcerative Colitis
Phases
DelveInsight’s report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Ulcerative Colitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ulcerative Colitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Colitis drugs.
Ulcerative Colitis Report Insights
- Ulcerative Colitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ulcerative Colitis drugs?
- How many Ulcerative Colitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ulcerative Colitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ulcerative Colitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ulcerative Colitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Oppilan Pharma
- Genentech
- Teva Branded Pharmaceutical
- Boehringer Ingelheim
- Sorriso Pharmaceuticals
- Reistone Biopharma
- Celgene
- AnaptysBio
- Rise Therapeutics
- Merck
- AltruBio
- AbbVie
- Immunic AG
- Kissei Pharmaceutical Co
- Lmito Therapeutics
- Morphic Therapeutic
- Oncostellae
- Palatin Technologies
- VTX002
- Vixarelimab
- TEV-48574
- Spesolimab
- SOR102
- SHR0302
- RPC1063
- Rosnilimab
- R-3750
- MK-7240
- ALTB-268
- ABBV-668
- IMU-838
- KSP-0243
- LMT503
- MORF-057
- OST-122
- PL8177
Please Note: It will take 7-8 business days to complete the report upon order confirmation.
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Ulcerative Colitis : Overview
- Introduction
- Structure
- Function
- Mechanism of action
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Assessment by Product Type
- Assessment by Stage and Product Type
- Ulcerative Colitis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Obefazimod: Abivax
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ABBV-668: AbbVie
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SOR102: Sorriso Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Mid Stage Products (Phase II)
- Preclinical Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Ulcerative Colitis - Collaborations Assessment- Licensing / Partnering / Funding
- Ulcerative Colitis - Unmet Needs
- Ulcerative Colitis - Market Drivers and Barriers
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.